Search

Your search keyword '"Álvarez-Sala, L."' showing total 29 results
Start Over Author "Álvarez-Sala, L."
29 results on '"Álvarez-Sala, L."'

7. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008

Author

Lobos, J.M., primary, Royo-Bordonada, M.Á., additional, Brotons, C., additional, Álvarez-Sala, L., additional, Armario, P., additional, Maiques, A., additional, Mauricio, D., additional, Sans, S., additional, Villar, F., additional, Lizcano, Á., additional, Gil-Núñez, A., additional, de Álvaro, F., additional, Conthe, P., additional, Luengo, E., additional, del Río, A., additional, Cortés, O., additional, de Santiago, A., additional, Varga, M.A., additional, Martínez, M., additional, and Lizarbe, V., additional

Published
2009
Full Text
View/download PDF

8. Adaptación española de la Guía Europea de Prevención Cardiovascular

Author

Brotons, C., primary, Royo-Bordonada, M.A., additional, Álvarez-Sala, L., additional, Armario, P., additional, Artigao, R., additional, Conthe, P., additional, de Álvaro, F., additional, de Santiago, A., additional, Gil, A., additional, Lobos, J.M., additional, Maiques, A., additional, Marrugat, J., additional, Mauricio, D., additional, Rodríguez-Artalejo, F., additional, Sans, S., additional, and Suárez, C., additional

Published
2005
Full Text
View/download PDF

9. Adaptación Española de la Guía Europea de Prevención Cardiovascular

Author

Brotons, C., primary, Royo-Bordonada, M.Á., additional, Álvarez-Sala, L., additional, Armario, P., additional, Artigao, R., additional, Conthe, P., additional, Álvaro, F. de, additional, Santiago, A. de, additional, Gil, A., additional, Lobos, J.M., additional, Maiques, A., additional, Marrugat, J., additional, Mauricio, D., additional, Rodríguez-Artalejo, F., additional, Sans, S., additional, and Suárez, C., additional

Published
2004
Full Text
View/download PDF

10. Adaptación española de la Guía Europea de Prevención Cardiovascular

Author

Brotonsa, C., primary, Royo-Bordonada, M.A., additional, Álvarez-Sala, L., additional, Armario, P., additional, Artigao, R., additional, Conthe, P., additional, de Álvaro, F., additional, de Santiago, A., additional, Gil, A., additional, Lobos, J.M., additional, Maiques, A., additional, Marrugat, J., additional, Mauricio, D., additional, Rodríguez-Artalejo, F., additional, Sans, S., additional, and Suárez, C., additional

Published
2004
Full Text
View/download PDF

11. Coxalgia de larga evolución

Author

Martin-Scapa, C., primary, Álvarez-Sala, L., additional, Bartolomé Martínez, P., additional, González Hernández, T., additional, and Vega San Vicente, F., additional

Published
2002
Full Text
View/download PDF

15. Alcohol y arteriosclerosis

Author

Gabarró, N., primary, Valderrama, M., additional, Duffort, M., additional, Álvarez-Sala, L., additional, and Millán, J., additional

Published
1999
Full Text
View/download PDF

17. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación Española del Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) 2008.

Author

Lobos, J. M., Royo-Bordonada, M. A., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano, A., Gil-Núñez, A., De Álvaro, F., Conthe, P., Luengo, E., del Río, A., Rico, O., de Santiago, A., Vargas, M. A., Martínez, M., and Lizarbe, V.

Subjects
CARDIOVASCULAR diseases, PREVENTIVE medicine, MEDICAL protocols, CARDIOVASCULAR emergencies, PREVENTION
Abstract

Copyright of Neurologia (Grupo ARS XXI de Comunicacion, S.A.) is the property of Grupo ARS XXI de Comunicacion, S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2009

23. European guidelines on cardiovascular disease prevention in clinical practice. Spanish adaptation CEIPC 2008,Guía europea de prevención cardiovascular en la práctica clínica. Adaptación Española del CEIPC 2008

Author

Lobos, J. M., Royo-Bordonada, M. A., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Didac Mauricio, Sans, S., Villar, F., Lizcano, A., Gil-Núñez, A., Álvaro, F., Conthe, P., Luengo, E., Del Río, A., Rico, O., Santiago, A., Vargas, M. A., Martínez, M., and Lizarbe, V.

24. European guidelines on cardiovascular disease prevention in clinical practice. Spanish adaptation of the CEIPC 2008,Guía Europea de prevención cardiovascular en la práctica clínica. Adaptación española del Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) 2008

Author

Lobos, J. M., Royo-Bordonada, M. A., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Didac Mauricio, Sans, S., Villar, F., Lizcano, A., Gil-Núñez, A., Álvaro, F., Conthe, P., Luengo, E., Del Río, A., Rico, O., Santiago, A., Vargas, M. A., Martínez, M., and Lizarbe, V.

28. Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing.

Author

Prieto-García A, Peligros MI, Pérez Tamayo I, Zubeldia JM, Álvarez-Sala L, and Lavilla C

Subjects
Humans, Quality of Life, Chronic Disease, Adrenal Cortex Hormones therapeutic use, Recurrence, Pulmonary Eosinophilia drug therapy, Asthma drug therapy, Anti-Asthmatic Agents therapeutic use
Abstract

Introduction: Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids., Case Study: We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal. Mepolizumab was started and maintained for 2 years and 6 months., Results: Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 wk with no disease relapse., Conclusion: Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal. Dose interval may be individualized under close monitoring, for a more efficient treatment, reducing medical costs while improving patients' quality of life.

Published
2024
Full Text
View/download PDF

29. Rare genetic variants with large effect on triglycerides in subjects with a clinical diagnosis of familial vs nonfamilial hypertriglyceridemia.

Author

De Castro-Orós I, Civeira F, Pueyo MJ, Mateo-Gallego R, Bolado-Carrancio A, Lamíquiz-Moneo I, Álvarez-Sala L, Fabiani F, Cofán M, Cenarro A, Rodríguez-Rey JC, Ros E, and Pocoví M

Subjects
Adolescent, Adult, Aged, Base Sequence, Female, Humans, Hyperlipoproteinemia Type IV blood, Male, Middle Aged, Mutation, Young Adult, Genetic Variation, Hyperlipoproteinemia Type IV diagnosis, Hyperlipoproteinemia Type IV genetics, Triglycerides blood
Abstract

Background: Most primary severe hypertriglyceridemias (HTGs) are diagnosed in adults, but their molecular foundations have not been completely elucidated., Objective: We aimed to identify rare dysfunctional mutations in genes encoding regulators of lipoprotein lipase (LPL) function in patients with familial and non-familial primary HTG., Methods: We sequenced promoters, exons, and exon-intron boundaries of LPL, APOA5, LMF1, and GPIHBP1 in 118 patients with severe primary HTG (triglycerides >500 mg/dL) and 53 normolipidemic controls. Variant functionality was analyzed using predictive software and functional assays for mutations in regulatory regions., Results: We identified 29 rare variants, 10 of which had not been previously described: c.(-16A>G), c.(1018+2G>A), and p.(His80Arg) in LPL; p.(Arg143Alafs*57) in APOA5; p.(Val140Ile), p.(Leu235Ile), p.(Lys520*), and p.(Leu552Arg) in LMF1; and c.(-83G>A) and c.(-192A>G) in GPIHBP1. The c.(1018+2G>A) variant led to deletion of exon 6 in LPL cDNA, whereas the c.(-16A>G) analysis showed differences in the affinity for nuclear proteins. Overall, 20 (17.0%) of the patients carried at least one allele with a rare pathogenic variant in LPL, APOA5, LMF1, or GPIHBP1. The presence of a rare pathogenic variant was not associated with lipid values, family history of HTG, clinical diagnosis, or previous pancreatitis., Conclusions: Less than one in five subjects with triglycerides >500 mg/dL and no major secondary cause for HTG may carry a rare pathogenic mutation in LPL, APOA5, LMF1, or GPIHBP1. The presence of a rare pathogenic variant is not associated with a differential phenotype., (Copyright © 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results